search
Back to results

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
irbesartan
placebo
PS433540
PS433540
PS433540
Sponsored by
Ligand Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, High Blood Pressure

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males or females 18 - 70 years
  • Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and < 180 mmHg and mean seated Diastolic Blood Pressure (DBP) > 90 and < 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two consecutive qualifying visits must be ≤ 10 mmHg.
  • Women of child-bearing potential (WOCBP) must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year).

Exclusion Criteria:

  • Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases.
  • History of malignancy other than adequately treated basal cell or squamous cell skin cancer.
  • Subjects with a history of myocardial infarction or New York Heart Association (NYHA) class II-IV heart failure.
  • Subjects with a history of cerebrovascular accident or transient ischemic attack.
  • Subjects with clinically significant cardiac conduction defects, including second or third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.
  • Subjects with hemodynamically significant valvular disease.
  • Subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.

Sites / Locations

  • Advanced Clinical Research 1000 Forrest Place Suite 2 Pell City
  • Premiere Pharmaceutical Research, LLC
  • Genova Clinical Research AZ
  • Advanced Clinical Research Institute
  • Associated Pharmaceutical Research Center
  • Clinical Trials Research CA
  • Long Beach Center for Clinical Research
  • National Research Institute
  • Superior Regional Research, LLC
  • Orange County Research Center
  • Westlake Medical Center
  • Univ. Clinical Research Deland, LLC.
  • Allan Graff
  • Jacksonville Center for Clinical Research
  • North County Medical
  • Q Clinical Research
  • Clinical Research Atlanta
  • East-West Medical Research Institute
  • Cedar Crosse Research Center
  • Midwest Institute for Clinical Research
  • MD Medical Research
  • Cary Medical Research
  • Metrolina Medical Research
  • Unifour Medical Research NC
  • Northstate Clinical Research
  • Triangle Medical Research NC
  • Crescent Medical Research
  • New Hanover Medical Rersearch
  • Peidmont Medical Research Associates
  • The Lindner Center
  • Delaware Smith Clinic
  • Smith Clinic
  • COR Clinical Research, L.L.C
  • Brandywine Clinical Research Center
  • Hypertension & Nephrology Inc
  • Punzi Medical Center
  • Innovative Clinical Trials
  • IMED Research PA
  • Hampton Roads Center for Clinical Research
  • Gemini Scientific LLC

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Active Comparator

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Irbesartan 300mg

Placebo

PS433540 200mg

PS433540 400mg

PS433540 800mg

Arm Description

Irbesartan 300 mg once daily

Blinded Placebo Treatment

PS433540 200mg once daily

PS433540 400mg once daily

PS433540 800mg once daily

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.

Secondary Outcome Measures

Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.

Full Information

First Posted
March 6, 2008
Last Updated
September 12, 2011
Sponsor
Ligand Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00635232
Brief Title
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
Official Title
A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ligand Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, High Blood Pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
261 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Irbesartan 300mg
Arm Type
Active Comparator
Arm Description
Irbesartan 300 mg once daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Blinded Placebo Treatment
Arm Title
PS433540 200mg
Arm Type
Experimental
Arm Description
PS433540 200mg once daily
Arm Title
PS433540 400mg
Arm Type
Experimental
Arm Description
PS433540 400mg once daily
Arm Title
PS433540 800mg
Arm Type
Experimental
Arm Description
PS433540 800mg once daily
Intervention Type
Drug
Intervention Name(s)
irbesartan
Other Intervention Name(s)
Avapro
Intervention Description
300 mg (2 x 150 mg capsules) once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo capsules once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
PS433540
Intervention Description
200 mg (2 x 100 mg capsules) once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
PS433540
Intervention Description
400 mg (4 x 100 mg capsules) once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
PS433540
Intervention Description
800 mg (8 x 100 mg capsules) once daily for 12 weeks
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time Frame
12 weeks
Title
The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females 18 - 70 years Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and < 180 mmHg and mean seated Diastolic Blood Pressure (DBP) > 90 and < 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two consecutive qualifying visits must be ≤ 10 mmHg. Women of child-bearing potential (WOCBP) must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year). Exclusion Criteria: Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases. History of malignancy other than adequately treated basal cell or squamous cell skin cancer. Subjects with a history of myocardial infarction or New York Heart Association (NYHA) class II-IV heart failure. Subjects with a history of cerebrovascular accident or transient ischemic attack. Subjects with clinically significant cardiac conduction defects, including second or third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication. Subjects with hemodynamically significant valvular disease. Subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rene Belder, MD
Organizational Affiliation
Ligand Pharmaceuticals
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Joel Neutel, MD
Organizational Affiliation
Orange County Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Advanced Clinical Research 1000 Forrest Place Suite 2 Pell City
City
Pell City
State/Province
Alabama
ZIP/Postal Code
35128
Country
United States
Facility Name
Premiere Pharmaceutical Research, LLC
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85282
Country
United States
Facility Name
Genova Clinical Research AZ
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85741
Country
United States
Facility Name
Advanced Clinical Research Institute
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Associated Pharmaceutical Research Center
City
Buena Park
State/Province
California
ZIP/Postal Code
90620
Country
United States
Facility Name
Clinical Trials Research CA
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
Long Beach Center for Clinical Research
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Superior Regional Research, LLC
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Orange County Research Center
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Westlake Medical Center
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
Univ. Clinical Research Deland, LLC.
City
Deland
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Allan Graff
City
Ft. Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
Facility Name
Jacksonville Center for Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
North County Medical
City
Sebastian
State/Province
Florida
ZIP/Postal Code
32958
Country
United States
Facility Name
Q Clinical Research
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30035
Country
United States
Facility Name
Clinical Research Atlanta
City
Stockbridge
State/Province
Georgia
ZIP/Postal Code
30281
Country
United States
Facility Name
East-West Medical Research Institute
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96814
Country
United States
Facility Name
Cedar Crosse Research Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Midwest Institute for Clinical Research
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Facility Name
MD Medical Research
City
Oxon Hill
State/Province
Maryland
ZIP/Postal Code
20745
Country
United States
Facility Name
Cary Medical Research
City
Cary
State/Province
North Carolina
ZIP/Postal Code
27518
Country
United States
Facility Name
Metrolina Medical Research
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28209
Country
United States
Facility Name
Unifour Medical Research NC
City
Hickory
State/Province
North Carolina
ZIP/Postal Code
28601
Country
United States
Facility Name
Northstate Clinical Research
City
Lenoir
State/Province
North Carolina
ZIP/Postal Code
28645
Country
United States
Facility Name
Triangle Medical Research NC
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27609
Country
United States
Facility Name
Crescent Medical Research
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
New Hanover Medical Rersearch
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Peidmont Medical Research Associates
City
Winston Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
The Lindner Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Delaware Smith Clinic
City
Delaware
State/Province
Ohio
ZIP/Postal Code
43015
Country
United States
Facility Name
Smith Clinic
City
Marion
State/Province
Ohio
ZIP/Postal Code
43302
Country
United States
Facility Name
COR Clinical Research, L.L.C
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
Brandywine Clinical Research Center
City
Downingtown
State/Province
Pennsylvania
ZIP/Postal Code
19335
Country
United States
Facility Name
Hypertension & Nephrology Inc
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02904
Country
United States
Facility Name
Punzi Medical Center
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Facility Name
Innovative Clinical Trials
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
IMED Research PA
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Hampton Roads Center for Clinical Research
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Gemini Scientific LLC
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53719
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

We'll reach out to this number within 24 hrs